Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "therapies"

989 News Found

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
News | August 28, 2025

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis


Thermo Fisher opens pipette manufacturing site in North Carolina
News | August 28, 2025

Thermo Fisher opens pipette manufacturing site in North Carolina

New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week


Giant antibody in humans acts like a brace against bacterial toxins
News | August 26, 2025

Giant antibody in humans acts like a brace against bacterial toxins

Protein L is known as a “superantigen” because it can bind antibodies in unusual ways


Dr. Reddy's launches novel drug for chronic constipation management
News | August 26, 2025

Dr. Reddy's launches novel drug for chronic constipation management

Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo


GSK forays into oncology in India with Jemperli and Zejula
News | August 25, 2025

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers


Parexel appoints Jim Anthony as CCO and President, Parexel Biotech
People | August 25, 2025

Parexel appoints Jim Anthony as CCO and President, Parexel Biotech

Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role


FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
Drug Approval | August 25, 2025

FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy

KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB


FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Drug Approval | August 24, 2025

FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control


FDA lifts hold on Rocket Pharma's gene therapy trial
News | August 22, 2025

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort